TrialAdvances in therapy2017

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.

Catherine S Tripp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.